Rapid Dose Therapeutics Provides Shareholder Update Regarding Vaccine Collaboration Agreement with Oakland Health Limited in the United Kingdom & More News Here

BURLINGTON, Ontario, May 12, 2022–(BUSINESS WIRE)–Rapid Dose Therapeutics Corp. (“RDT“), (CSE: DOSE), a Canadian biotechnology firm leveraging an progressive, proprietary oral supply platform, offers the following replace relating to the signing of quite a lot of strategically important agreements with Oakland Health Limited (working as “RD Therapeutics“) to assist and speed up the growth and commercialization of the Company’s QuickStrip™ system for COVID-19 vaccines (the “QuickStripVax“).

“These agreements with RD Therapeutics significantly enhance our non-needle initiative to drive a broader international deployment of COVID-19 vaccines and other potential mRNA applications. Vaccines embedded into our proprietary QuickStrip solution address many of the challenges facing vaccine delivery, in particular the cold-chain requirements and lack of medical resources, especially in developing nations,” mentioned Mark Upsdell, CEO Rapid Dose Therapeutics. “Our UK partners, including Ailene Thiel and Diane Moss, bring valuable relationships with business leaders, pharmaceutical executives and governments in the United Kingdom and the European Union, which will be paramount to supporting rapid development and expansion of our needle-free vaccine delivery platform.”

As introduced in RDT’s press launch on March 7, 2022, Ms. Thiel was a contributor to the #100DaysMission First Implementation Report, actively helps the 100 Days Mission and was an invited visitor representing RDT at the Coalition for Epidemic Preparedness Innovations’ (CEPI) Global Pandemic Preparedness Summit on March 7-8 of this yr in London. The Summit introduced collectively world leaders from governments, worldwide companies, science and academia, trade, philanthropy, and civil society to proceed the helpful work being accomplished to fulfill international unmet medical wants and mobilize the crucial assets required for CEPI’s $3.5 billion pandemic plan to make sure a extra equitable response to future pandemics.

Ms. Thiel’s standing inside these necessary teams has supplied the Company with a chance to develop international consciousness of RDT’s needle-free vaccine platform as a viable answer constant with the mandate of the 100 Days Mission.

Story continues

“We are pleased that Mark Upsdell and the leadership team at RDT recognize the value we provide as their UK and European partner,” mentioned Ailene Thiel, CEO, RD Therapeutics. “We are confident that our relationships with governments and within the global pharmaceutical sector will be extremely valuable in supporting the mobilization of a robust clinical program for needle-free, orally-delivered vaccines. Vaccines delivered on RDT’s oral thin-film delivery technology have the potential to increase access to vaccination for some of the hardest to reach sectors of the world’s population, dramatically reduce CO2 emissions associated with traditional vaccines manufacture and transportation, and provide a superior patient experience. In addition to SARS-CoV-2, our roadmap includes research into deploying RDT’s oral thin-film technology as a delivery system for other currently available vaccines to address diseases that, year upon year, kill millions of people worldwide. We are proud to be part of this initiative, which has enormous potential to make a difference in the lives of so many.”

Details of the Agreements
The agreements (i) crystallize the rigorously crafted relationship between RDT and RD Therapeutics and its principals by a Shareholders’ Agreement which grants RD Therapeutics a 5% curiosity in RDT’s newly created wholly-owned subsidiary, Rapid Dose Therapeutics (UK) Ltd. (“UK Co“). UK Co shall be granted the unique worldwide license to promote merchandise derived from the Intellectual Property behind the QuickStripVax and (ii) set out, by Collaboration and Services Agreements, the obligations of RD Therapeutics to maximise and speed up the Development of the QuickStripVax resulting in commercialization. In consideration of the obligations created in these agreements, RDT has granted a Royalty to RD Therapeutics in the quantity of two.5% of the web promoting value (as outlined) derived from the gross sales generated from the licensing association mentioned above.

About Rapid Dose Therapeutics Corp.
Rapid Dose Therapeutics is a Canadian biotechnology firm revolutionizing drug supply by innovation. The Company’s flagship product QuickStrip™ is a skinny, orally dissolvable movie, that may be infused with an infinite checklist of lively substances, together with nutraceuticals, prescribed drugs and vaccines, which are delivered rapidly into the bloodstream, ensuing in fast onset of the lively ingredient.
www.rapid-dose.com

About Oakland Health Limited Operating as “RD Therapeutics”
Driven by science, know-how and scientific proof, RD Therapeutics was shaped by a multidisciplinary staff of trade specialists with international expertise throughout the know-how, pharmaceutical and nutraceutical industries. The firm’s skilled trajectory has taught it the significance of being at the forefront of analysis and technological advances in product growth to deliver to market a singular vary of merchandise that can assist to create a society in which well being and wellness as a lifestyle is inside the attain of all.
www.rdtherapeutics.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:
Certain info in this information launch could comprise forward-looking info inside the which means of relevant securities legal guidelines. Any statements which are contained in this information launch that aren’t statements of historic reality could also be deemed to be forward-looking statements. Forward-looking statements are sometimes recognized by phrases resembling “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend”, “will”, “could”, “are planned to”, “are expected to” or the adverse of those phrases and comparable expressions. Statements containing forward-looking info, together with, with out limitation, in respect of the supply of apparatus and merchandise utilizing the QuickStrip™ product supply methodology, the era of recurring revenues, as at the date of this information launch, the plans, estimates, forecasts, projections, expectations or beliefs of RDT administration as to future occasions or outcomes and are believed to be affordable primarily based on info presently out there to RDT administration. Forward-looking statements essentially contain identified and unknown dangers, together with, with out limitation, dangers related with common financial situations; opposed trade occasions; advertising prices; lack of markets; termination of WLM agreements; future legislative and regulatory developments involving hashish; incapability to entry ample capital from inner and exterior sources, and/or incapability to entry ample capital on beneficial phrases; the hashish trade in Canada usually, revenue tax and regulatory issues; the skill to implement its enterprise methods; competitors; forex and rate of interest fluctuations and different dangers. Readers are cautioned that the foregoing checklist shouldn’t be exhaustive. There may be no assurance that statements of forward-looking info, though thought-about affordable by RDT administration at the time of preparation, will show to be correct as there may be no assurance that the plans, intentions or expectations upon which they’re primarily based will happen. Actual outcomes and future occasions might differ materially from these anticipated in such forward-looking statements. Readers shouldn’t place undue reliance on forward-looking statements. Forward-looking statements contained in this information launch are expressly certified by this cautionary assertion.

View supply model on businesswire.com: https://www.businesswire.com/news/home/20220512005166/en/

Contacts

RDT Investor:
Mark Upsdell, CEO
[email protected]
416-477-1052

Media:
Canada/United States
Dara Willis
[email protected]
416-836-9272

United Kingdom/Europe
Stephanie Gillespie
[email protected]
+ 1 242 815 9810

I’ve tried to offer all types of stories to all of you latest news today 2022 by this web site and you’re going to like all this information very a lot as a result of all the information we at all times give in this information is at all times there. It is on trending subject and no matter the newest information was

it was at all times our effort to achieve you that you simply maintain getting the newest information and also you at all times maintain getting the info of stories by us without cost and likewise inform you folks. Give that no matter info associated to different forms of information shall be

made out there to all of you so that you’re at all times related with the information, keep forward in the matter and maintain getting today news all forms of information without cost until in the present day as a way to get the information by getting it. Always take two steps ahead